How does Burna AI describe its mission?

To build the safety data quality layer for oncology drug development, from clinical trials through decades of postmarket surveillance. The long-term vision is the Flatiron model applied to the highest-stakes data in drug development. Flatiron captured real-world evidence during active treatment and was acquired by Roche for $1.9 billion. Flatiron was pre-AI and single-sided. Burna AI is AI-native and two-sided: structured, citation-bound, attribution-scored adverse event data from Phase 1 trial through 20 years postmarket.